Picture Berlin Partner Top News from HealthCapital Berlin-Brandenburg 650x100px
Document › Details

BaseLaunch ( (10/3/19). "Press Release: 15 Companies Chosen for Phase 1". Basel.

Region Region Basel BS
  Country Switzerland
Organisations Organisation BaseLaunch Accelerator (Basel)
  Group Basel (govt city)
  Organisation 2 Alibion AG
Products Product business park management / science park management

The selection committee has chosen 15 promising projects for Phase I. The projects all focus on developing innovative technologies to dramatically change patient outcomes in a variety of therapeutic areas. All of our project teams are eager to make a significant impact on improving people’s lives.

The aim is now, together with BaseLaunch, Pharma partners, as well as a deep network of experts, further assess each project and help to clearly articulate the near/mid- term milestones (preclinical, regulatory, commercial, and much more) required to further de-risk the science and build the companies.

The companies are as follows in alphabetical order:

Alibion is a pre-clinical stage drug-development company developing the first personalized therapy against Rheumatoid arthritis.

Biotech in stealthmode
Company in stealth mode developing an antibody-based tumor therapy against a first-in-class target in the tumor microenvironment.

Biotech in stealthmode
Company in stealth mode developing novel inhibitors of the inflammasome.

Biotech in stealthmode
Platform for finding new targets and developing novel drugs for solid cancers.

CMET Pharmaceuticals
CMET Pharmaceuticals aims to develop novel therapies for the treatment of metastatic cancers, tailored to target circulating tumour cell clusters.

FoRx Therapeutics is developing therapeutics that exploit the presence of DNA replication STRESS in human cancers.

GEBAMO is bringing CRISPR-Cas12a technology forward.

ImmProfile is advancing innovative discoveries and solutions in immune oncology.

Innervation Pharmaceuticals
Innervation Pharmaceuticals is a pre-clinical phase biotech. Its patented, solid-phase transfection platform is used for genome-wide screening services and the discovery of genes that boost neuronal regrowth after spinal cord injury.

INSIDER Therapeutics
INSIDER Therapeutics is a preclinical stage spin-off project from University of Zurich. It is developing first-in-class small molecule anticancer therapeutics that modulate the epitranscriptomic code.

ISARNA is a clinical stage Biotech Company, addressing high unmet medical need in Ophthalmology and beyond by developing innovative, targeted, first in class antisense blockbuster therapies for major blinding diseases.

PharmaBiome pioneers bacterial mixes as microbiome therapeutics in IBD and oncology based on our mixed-culture technology.

SunRegen develops neuroprotective drugs for neurodegenerative diseases.

Synoesis is developing a first-in-class therapeutic to stop Parkinson’s disease.

TOLREMO is a cancer drug resistance company. Our resistance-preventing small molecules boost the long-term efficacy of existing cancer drugs to prolong patient survival.

Record changed: 2023-06-05


Picture EBD Group Biotech Showcase 2024 San Francisco 650x200px

More documents for Basel (govt city)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Stier Group MIXiii Lifescience Healthtech Conference 650x300px

» top